摘要
目的探究表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)耐药的非小细胞肺癌(NSCLC)患者其临床检测血清有丝裂原活化蛋白激酶(MAPK)、血管内皮生长因子(VEGF)、微小RNA-532-3p(microRNA-532-3p,miR-532-3p)检测的价值。方法回顾性分析2018年7月~2023年7月临泉县人民医院收治的80例EGFR-TKIs耐药的NSCLC患者临床资料作为观察组,同期就诊80例非耐药的NSCLC患者临床资料作为对照组。比较两组患者血清MAPK、VEGF、miR-532-3p水平变化,利用Spearman法分析血清MAPK、VEGF、miR-532-3p水平与其耐药患者分期相关性。依据患者预后情况将观察组分为预后良好亚组与预后不良亚组,比较两亚组患者血清MAPK、VEGF、miR-532-3p水平,同时绘制ROC曲线分析血清MAPK、VEGF、miR-532-3p水平对EGFR-TKIs耐药的NSCLC患者预后情况的预测效能。结果观察组血清MAPK、VEGF、miR-532-3p水平均高于对照组(t=30.243、8.293、12.607,P<0.05),且观察组血清MAPK、VEGF、miR-532-3p水平与其TNM分期存在正相关性(r=0.456、0.508、0.568,P<0.05)。预后良好亚组血清MAPK、VEGF、miR-532-3p水平均显著低于预后不良亚组(t=11.117、9.854、24.101,P<0.05)。血清MAPK、VEGF、miR-532-3p预测EGFR-TKIs耐药的NSCLC患者预后AUC值分别为0.808、0.790、0.921(P<0.05)。结论血清MAPK、VEGF、miR-532-3p与EGFR-TKIs耐药NSCLC患者疾病严重程度存在相关性,可作为评估其预后的生物学指标。
Objective To investigate the clinical significance of detecting serum levels of mitogen-activated protein kinase(MAPK),vascular endothelial growth factor(VEGF),and miR-532-3p in patients with EGFR-TKIs-resistant non-small cell lung cancer(NSCLC).Methods The clinical data of 80 patients with EGFR-TKIs-resistant NSCLC in the hospital from July 2018 to July 2023 were retrospectively analyzed and the patients were enrolled as observation group.The clinical data of 80 patients with nonresistant NSCLC during the same period were retrospectively analyzed and the patients were included in control group.The changes of serum MAPK,VEGF and miR-532-3p levels were compared between the two groups.Spearman method was used to analyze the correlation between serum MAPK,VEGF and miR-532-3p levels and staging of drug-resistant patients.According to the prognosis status of patients,the patients in observation group were divided into good prognosis subgroup and poor prognosis subgroup,and serum MAPK,VEGF and miR-532-3p levels were compared between the two subgroups.ROC curve was drawn to analyze the predictive efficiency of serum MAPK,VEGF and miR-532-3p levels on the prognosis in NSCLC patients with EGFR-TKIs resistance.Results In the observation group,the serum levels of MAPK,VEGF,and miR-532-3p were significantly higher compared to the control group(t=30.243,8.293,12.607,P<0.05),and these markers showed a positive correlation with TNM staging in the observation group(r=0.456,0.508,0.568,P<0.05).Serum levels of MAPK,VEGF and miR-532-3p in good prognosis subgroup were significantly lower than those in poor prognosis subgroup(t=11.117,9.854,24.101,P<0.05).The AUCs of serum MAPK,VEGF and miR-532-3p in predicting the prognosis in NSCLC patients with EGFR-TKIs resistance were 0.808,0.790 and 0.921 respectively(P<0.05).Conclusion Serum MAPK,VEGF and miR-532-3p are correlated with disease severity in patients with EGFR-TKIs-resistant NSCLC,and can be used as biological indicators to evaluate the prognosis.
作者
张玉贺
马辉辉
Zhang Yuhe;Ma Huihui(Department of Oncology,Linquan County People's Hospital,Fuyang 236400,China)
出处
《中华保健医学杂志》
2025年第1期27-30,共4页
Chinese Journal of Health Care and Medicine
基金
安徽省卫生健康科研项目(AHWJ2022b119)。
